Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of oral deucrictibant for acute hereditary angioedema attacks
2023-505766-28-00Phase 3Authorised
- Sponsor
- Pharvaris
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, open-label trial of deucrictibant in hereditary angioedema (HAE) and Hereditary Angioedema With Normal C1-Inhibitor (HAE-nl-C1-INH) (2 arms), sponsored by Pharvaris. Primary endpoints: Adverse events, Vital signs and 3 more. Planned start Oct 2022; status: authorised.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)Hereditary Angioedema With Normal C1-Inhibitor (HAE-nl-C1-INH)
Beyond the preview
Go deeper on 2023-505766-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505766-28-00.